DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nam, Su Youn | - |
dc.contributor.author | Kim, Joo Sung | - |
dc.contributor.author | Kim, Jung Mogg | - |
dc.contributor.author | Lee, Jong Yeul | - |
dc.contributor.author | Kim, Nayoung | - |
dc.contributor.author | Jung, Hyun Chae | - |
dc.contributor.author | Song, In Sung | - |
dc.date.accessioned | 2022-10-07T10:39:35Z | - |
dc.date.available | 2022-10-07T10:39:35Z | - |
dc.date.created | 2022-08-26 | - |
dc.date.issued | 2008-02 | - |
dc.identifier.issn | 1535-3702 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/172138 | - |
dc.description.abstract | Previously, we have shown that DA-6034, a synthetic derivative of flavonoid eupatilin, inhibited NF-kappa B activation in colon epithelial cells and prevented trinitrobenzene sulfonic acid-induced rat colitis. The aim of this study was to investigate the preventive and therapeutic effect of DA-6034 on dextran sulfate sodium (DSS) - induced colitis and on inflammation-related cancer. C57BL/6 mice were given 4% DSS for 5 days with and without DA-6034 in the acute preventive model. In the acute therapeutic model, mice were given 4% DSS for 5 days followed by rectal administration of DA-6034. Colitis was quantified by body weight, disease activity index (DAI), colon length, and histology. In the inflammation-related cancer model, mice were given a single intraperitoneal injection of azoxymethane, then three cycles of 2% DSS for 5 days, then 2 weeks of free water consumption. Apoptosis was determined by in situ terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay, and the expression of Ki-67, phospho-kappa B kinase alpha (IKK alpha), and COX-2 were evaluated by immunohistochemistry. In both the acute preventive and acute therapeutic models, DA-6034 significantly attenuated DSS-induced weight loss, an increase in DAI, and a shortening of colon length. DA-6034 - treated mice maintained crypt architecture and revealed a scanty infiltration of inflammatory cells in both the preventive and therapeutic models. In the inflammation-related cancer model, DA-6034 reduced the number of colon tumors and ameliorated weight loss and shortening of colon length. DA-6034 strongly enhanced apoptosis and inhibited the expression of COX-2 and phospho-IKK alpha in inflammation-related colon cancer models. Our results suggest that DA-6034 prevents acute murine colitis and inhibits inflammation-related colon carcinogenesis. DA-6034 could be a potential therapeutic agent for inflammatory bowel disease. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.title | DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jung Mogg | - |
dc.identifier.doi | 10.3181/0707-RM-186 | - |
dc.identifier.scopusid | 2-s2.0-38949148964 | - |
dc.identifier.wosid | 000252764500010 | - |
dc.identifier.bibliographicCitation | EXPERIMENTAL BIOLOGY AND MEDICINE, v.233, no.2, pp.180 - 191 | - |
dc.relation.isPartOf | EXPERIMENTAL BIOLOGY AND MEDICINE | - |
dc.citation.title | EXPERIMENTAL BIOLOGY AND MEDICINE | - |
dc.citation.volume | 233 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 180 | - |
dc.citation.endPage | 191 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | INFLAMMATORY-BOWEL-DISEASE | - |
dc.subject.keywordPlus | NF-KAPPA-B | - |
dc.subject.keywordPlus | ULCERATIVE-COLITIS | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | EPITHELIAL-CELLS | - |
dc.subject.keywordPlus | CYCLOOXYGENASE 2 | - |
dc.subject.keywordPlus | MURINE COLITIS | - |
dc.subject.keywordPlus | ANIMAL-MODELS | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | DA-6034 | - |
dc.subject.keywordAuthor | inflammatory bowel disease | - |
dc.subject.keywordAuthor | colon cancer | - |
dc.identifier.url | https://journals.sagepub.com/doi/10.3181/0707-RM-186 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.